Atsuto Inoue
Mishima, 6188585, Japan
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 10 publications
Effect of etelcalcetide on parathyroid hormone secretion by primary hyperparathyroidism patient-derived primary parathyroid cells.
Journal: Journal of bone and mineral metabolism
Published: May 21, 2020
Etelcalcetide decreases the PTH-calcium setpoint without changing maximum and minimum PTH secretion in mice with primary hyperparathyroidism.
Journal: Journal of bone and mineral metabolism
Published: May 01, 2020
Pharmacology of Parsabiv® (etelcalcetide, ONO-5163/AMG 416), a novel allosteric modulator of the calcium-sensing receptor, for secondary hyperparathyroidism in hemodialysis patients.
Journal: European journal of pharmacology
Published: May 21, 2018
The pharmacological profile and the clinical efficacy of the world's 1st intravenous calcimimetics; etelcalcetide hydrochloride (Parsabiv®).
Journal: Nihon yakurigaku zasshi. Folia pharmacologica Japonica
Published: August 11, 2017
Abnormal spermatogenesis and male infertility in testicular zinc finger protein Zfp318-knockout mice.
Journal: Development, growth & differentiation
Published: November 07, 2015
Using zebrafish in systems toxicology for developmental toxicity testing.
Journal: Congenital anomalies
Published: September 07, 2015
Discovery of Gemilukast (ONO-6950), a Dual CysLT1 and CysLT2 Antagonist As a Therapeutic Agent for Asthma.
Journal: Journal of medicinal chemistry
Published: July 23, 2015
Effects of ONO-6950, a novel dual cysteinyl leukotriene 1 and 2 receptors antagonist, in a guinea pig model of asthma.
Journal: European journal of pharmacology
Published: May 14, 2015
Discovery of a potent, orally available dual CysLT₁ and CysLT₂ antagonist with dicarboxylic acid.
Journal: Bioorganic & medicinal chemistry
Published: January 27, 2015
Showing 1-10 of 10
Last Updated: 09/26/2026